Literature DB >> 17140851

What is the blood-brain barrier (not)?

Ingo Bechmann1, Ian Galea, V Hugh Perry.   

Abstract

In 1900, summarizing his experiments with toxins and Ehrlich's earlier observations with intravital dyes, the Berlin physician Lewandowski concluded that "brain capillaries must hold back certain molecules". Illustrating this phenomenon with persuasive beauty, the subsequently evolving metaphor of a 'Bluthirnschranke' (blood-brain barrier, BBB) gained wide acceptance, but the extension of its meaning into the context of inhibiting leukocyte recruitment into the brain is imprecise. On the basis of the original work by Ehrlich, Lewandowski and Goldmann we re-define the BBB as a capillary barrier for solutes, and clarify that leukocyte recruitment requires two differentially regulated steps: (i) passage across postcapillary venules into Virchow-Robin spaces, and (ii) subsequent progression across the glia limitans into the neuropil. We propose that the second step frequently involves perivascular antigen-recognition and the induction of ectoenzymes, for example matrix metalloproteinases (MMPs).

Entities:  

Mesh:

Year:  2006        PMID: 17140851     DOI: 10.1016/j.it.2006.11.007

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  181 in total

1.  In Vivo Imaging of Venous Side Cerebral Small-Vessel Disease in Older Adults: An MRI Method at 7T.

Authors:  C E Shaaban; H J Aizenstein; D R Jorgensen; R L MacCloud; N A Meckes; K I Erickson; N W Glynn; J Mettenburg; J Guralnik; A B Newman; T S Ibrahim; P J Laurienti; A N Vallejo; C Rosano
Journal:  AJNR Am J Neuroradiol       Date:  2017-08-03       Impact factor: 3.825

Review 2.  Immunotherapy for primary brain tumors: no longer a matter of privilege.

Authors:  Peter E Fecci; Amy B Heimberger; John H Sampson
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

3.  Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology.

Authors:  Daniel Larocque; Nicholas S R Sanderson; Josée Bergeron; James F Curtin; Joe Girton; Mia Wibowo; Niyati Bondale; Kurt M Kroeger; Jieping Yang; Liliana M Lacayo; Kevin C Reyes; Catherine Farrokhi; Robert N Pechnick; Maria G Castro; Pedro R Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

4.  Expression of astrocytic type 2 angiotensin receptor in central nervous system inflammation correlates with blood-brain barrier breakdown.

Authors:  Laila Füchtbauer; Henrik Toft-Hansen; Reza Khorooshi; Trevor Owens
Journal:  J Mol Neurosci       Date:  2010-04-23       Impact factor: 3.444

Review 5.  Trafficking of immune cells in the central nervous system.

Authors:  Emma H Wilson; Wolfgang Weninger; Christopher A Hunter
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

Review 6.  The myeloid cells of the central nervous system parenchyma.

Authors:  Richard M Ransohoff; Astrid E Cardona
Journal:  Nature       Date:  2010-11-11       Impact factor: 49.962

7.  CD8 T cell-initiated blood-brain barrier disruption is independent of neutrophil support.

Authors:  Holly L Johnson; Yi Chen; Fang Jin; Lisa M Hanson; Jeffrey D Gamez; Istvan Pirko; Aaron J Johnson
Journal:  J Immunol       Date:  2012-07-06       Impact factor: 5.422

Review 8.  Bridge between neuroimmunity and traumatic brain injury.

Authors:  Matthew L Kelso; Howard E Gendelman
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 9.  Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Clin Immunol       Date:  2017-07-15       Impact factor: 3.969

10.  Lumbar Myeloid Cell Trafficking into Locomotor Networks after Thoracic Spinal Cord Injury.

Authors:  Christopher N Hansen; Diana M Norden; Timothy D Faw; Rochelle Deibert; Eric S Wohleb; John F Sheridan; Jonathan P Godbout; D Michele Basso
Journal:  Exp Neurol       Date:  2016-05-16       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.